European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 17 · Tue 6 Oct 

Molecules

Mebufotenin

5-MeO-DMT, BPL-003, GH001

2 assets6 European trial records1 deal

Chemical class
tryptamine alkaloid
Mechanism
Not independently verified. Acquirer release describes the pipeline as rapid-acting neuroplastogens designed to restore synaptic connectivity. Recorded as the company's characterisation, not ours.

Assets

European trials

Czechia 2

Germany 5

Ireland 2

Netherlands 3

Poland 4

Spain 4

Deals

Our calls

  • Issue 14OpenLilly does not name BPL-003, VLS-01 or mebufotenin in its Q3 2026 earnings press release, earnings deck, prepared remarks or Q&A, as published on the day of the release. Our read of whether the acquired compounds are a pipeline priority to Lilly's shareholders.
  • Issue 7OpenWithin 12 months of the Lilly/AtaiBeckley deal closing, neither BPL-003 nor VLS-01 will have a registered Phase 3 trial carrying ANY EU-member-state site, AND Lilly will have disclosed no EMA pathway for either drug. Our read of the deal's incentives, not Lilly's stated plan.
  • Issue 5OpenAtaiBeckley's BPL-003 Phase 3 program, when it registers, will use an ADJUNCTIVE design (patients stay on a stable SSRI, no antidepressant washout mandated). BPL-003 commits to the adjunctive camp, not the washout camp (Compass/EPIsoDE).
  • Issue 3MISSAtaiBeckley will report first BPL-003 Phase 3 patient dosed in Q3 2026 (after 30 June, before 30 September).
  • Issue 2HITAtaiBeckley will NOT announce first BPL-003 Phase 3 patient dosed before 30 June 2026. Expects initiation language near the wire; confirmed dosing slips to Q3.

Record history